Abstract
Herceptin (trastuzumab) is a human monoclonal antibody that interferes with the HER2 receptor. It is currently the only FDA-approved therapeutic antibody for HER2-positive breast cancer. This article will present the mechanism at action as well as the clinical role at this monoclonal antibody.
Highlights
ABBREVIATIONS: FDA ϭ US Food and Drug Administration; HER, HER2, HER3, and HER4 ϭ human epidermal growth factor receptors
Trastuzumab (Herceptin) is humanized monoclonal antibody that interferes with the HER2 receptor
Ligand binding to the extracellular domain promotes formation of dimmers, homodimers, or heterodimers, activating tyrosine kinase, and triggering a cascade of complex cell biochemistry that regulates various cell functions such as cell proliferation, angiogenesis, apoptosis, adhesion, and motility (Fig 1).[2,3]
Summary
ABBREVIATIONS: FDA ϭ US Food and Drug Administration; HER, HER2, HER3, and HER4 ϭ human epidermal growth factor receptors. It is currently the only FDA-approved therapeutic antibody for HER2-positive breast cancer. Ligand binding to the extracellular domain promotes formation of dimmers, homodimers (between monomers of same receptor), or heterodimers (between the bound receptor and other members of the HER family), activating tyrosine kinase, and triggering a cascade of complex cell biochemistry that regulates various cell functions such as cell proliferation, angiogenesis, apoptosis, adhesion, and motility (Fig 1).[2,3]
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
